# Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

> **NCT02871323** · PHASE1 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Primary Myelofibrosis

## Interventions

- **BIOLOGICAL:** Durvalumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02871323
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2016-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI decided to withdraw the study after it opened for enrollment but before any patients were enrolled
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871323, "Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02871323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*